Glimicon-DS Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 1000mg, formulated for sustained release to provide effective glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The sustained-release formulation ensures a gradual release of active ingredients, promoting better tolerability and adherence by minimizing gastrointestinal side effects commonly associated with metformin. Glimicon-DS is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on metformin alone or in combination with other antidiabetic agents. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and patient tolerance. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. This medication should be used under medical supervision with appropriate lifestyle modifications to optimize diabetes management and reduce the risk of long-term complications.